Avadel Pharmaceuticals (AVDL) Operating Expenses (2016 - 2021)
Historic Operating Expenses for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2021 value amounting to $23.1 million.
- Avadel Pharmaceuticals' Operating Expenses rose 6224.4% to $23.1 million in Q4 2021 from the same period last year, while for Sep 2022 it was $23.1 million, marking a year-over-year decrease of 6982.39%. This contributed to the annual value of $85.5 million for FY2021, which is 41786.43% up from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Operating Expenses of $23.1 million as of Q4 2021, which was up 6224.4% from $25.7 million recorded in Q3 2021.
- Avadel Pharmaceuticals' 5-year Operating Expenses high stood at $96.3 million for Q4 2018, and its period low was -$30.2 million during Q2 2020.
- Moreover, its 5-year median value for Operating Expenses was $20.6 million (2017), whereas its average is $23.9 million.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Operating Expenses crashed by 23714.16% in 2020, and later skyrocketed by 17268.87% in 2021.
- Over the past 5 years, Avadel Pharmaceuticals' Operating Expenses (Quarter) stood at $38.8 million in 2017, then surged by 148.1% to $96.3 million in 2018, then tumbled by 80.96% to $18.3 million in 2019, then decreased by 22.25% to $14.3 million in 2020, then surged by 62.24% to $23.1 million in 2021.
- Its last three reported values are $23.1 million in Q4 2021, $25.7 million for Q3 2021, and $21.9 million during Q2 2021.